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bine treatment could be considered as an optimal option for these p. We 
retrospectively evaluated efﬁcacy and toxicity of oral vinorelbine ad-
ministered as single agent for ﬁrst-line NSCLC treatment in elderly p. 
Methods: 1 cycle was equivalent to a 3-week period. Treatment 
consisted of oral vinorelbine 60 mg/m2/week during the ﬁrst 3 weeks, 
escalating to 80 mg/m2/week if no grade 4 or no more than two grade 3 
neutropenia were observed during ﬁrst cycle. At 80 mg/m2, if grade 4 
or 2 consecutive grade 3 neutropenia ocurred, the dose was reduced to 
60 mg/m2. Treatment was administered for 6 cycles, unless progression 
of the disease was observed earlier.
Results: Data on 46 p were collected in 11 Spanish centres. Median 
age was 77 years (range 70-85). Male, 87%; female, 13%. ECOG PS 0, 
26.8%; 1, 68.3%; 2, 4.9%. Stage IIIA, 4.3%; IIIB, 30.4%; IV, 65.2%. 
Histology: scamous, 56.5%; adenocarcinoma, 28.3%. Self-sufﬁciency 
in ADL and IADL was 82.5% and 55% of the p analyzed. 81.9% of the 
p had comorbidities. 46 p are available for toxicity and 27 for response. 
Median cycles: 3 (1-8). 158 cycles were performed, 13.4% were 
delayed and 5.4% had dose reduction. Hematological toxicities (%p): 
grade 3/4 neutropenia, 8.7%/8.7%. Grade 3 non-hematological toxici-
ties: asthenia, 6.5%; anorexia, 4.3%; respiratory, 4.3%; pain, 4.3%; 
nausea and vomiting, 2.2%. No grade 4 non-hematological toxicities 
were reported. In the evaluable p, 3 PR (11.1%) and 11 SD (40.7%) 
were reported (disease control 51.8%). With a median follow-up of 
3.4 months (m), median survival for the whole population was 6.37 m, 
progression free survival 3 m. 
Conclusions: This trial conﬁrms the results of previous studies with 
single agent oral vinorelbine in elderly NSCLC p. It has been shown 
that this treatment offers a reasonable control of disease, with easy ad-
ministration and a favorable toxicity proﬁle for this speciﬁc population.
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Background and Objective: How to improve the postoperative 5-year 
survival rate for lung cancer and to give more patients a chance of 
surgery have become research hot spots. The aim of this research is 
to evaluate the clinical and pathohistological responses and effects of 
preoperative bronchial artery infusion (BAI) chemotherapy in patients 
with locally advanced (stage III) non-small cell lung cancer (NSCLC). 
Methods: A total of 92 cases with locally advanced NSCLC were ran-
domly divided into two groups. BAI group received BAI chemotherapy 
for 2 cycles before surgical resection. Surgery group received operation 
only. The complete resection rate and clinical response were compared 
between the two groups. 
Results: In the BAI group, the clinical response rate and the patho-
histological response rate were 68.3% and 51.3% respectively. The 
complete resection rate in the BAI was 89.7%, which was signiﬁcantly 
higher than that in the surgery group (72.5% )(P<0.05). The 1- and 2-
year survival rates were 100% and 74.4% in the BAI group, and 94.1% 
and 60.0% in the surgery group.
Conclusion: BAI neoadjuvant chemotherapy is safe and effective, 
which has a good clinical and pathohistological response. It might 
increase the complete resection rate of the tumor of the tumor and 
improve the long-term survial rate of stage III NSCLC patients.
This work was supported by grants from Foundation of Science and 
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Background: We previously reported the outcomes of ATP-CRA-
guided platinum-based 2-drug chemotherapy for unresectable NSCLC 
(CANCER, in press). The study showed more favorable response and 
survival in chemo-sensitive subgroup than in chemo-resistant subgroup 
within assay-guided chemotherapy group. We retrospectively compared 
outcomes of assay-guided chemotherapy and empirical chemotherapy 
in this study.
Methods: From Sep. 2003 to Oct. 2005, we performed an in vitro 
chemosensitivity test, ATP-CRA. According to the assay results, plati-
num-based 2-drug chemotherapy was given to patients with chemo-
naïve, unresectable NSCLC. At the same period, medical records of 
unresectable NSCLC patients receiving platinum-based empirical 
chemotherapy were reviewed retropectively. Prognostic variables such 
as performance status (PS), stage, and chemotherapy regimen were 
matched with the ratio of 1: 3-4. Chemotherapy response and progrers-
sion-free survival (PFS) were compared between the assay-guided and 
empirical chemotherapy groups. 
Results: Eighty-two patients were enrolled. Eighteen were included 
in assay-guided group (AG) and 64 in empirical group (EG). Seventy 
(85.4%) patients had Eastern Cooperative Oncology Group (ECOG) 
PS of 0-1 and 12 (14.6%) had ECOG PS of 2. Stage IIIB was in 24 
(29.3%) patients and stage IV in 58 (70.7%). Fifty (61.0%) patients 
received paclitaxel plus platinum and 32 (39.0%) received gemcitabine 
plus platinum. These 3 prognosticators were well matched in the 
determined ratio. Other variables such as age, sex, brain metastasis, and 
histology were not also signiﬁcantly different between the 2 groups. 
The median cycles of admistered chemotherapy were 3 in AG and 4 
in EG. (P=0.267). AG showed a trend for higher response rate (50.0% 
vs 37.5% in EG; P=0.339). However, the median PFS was not dif-
ferent between the 2 groups (4.4 months in AG vs 4.4 months in EG; 
P=0.624).
Conclusions: Clinical outcomes of ATP-CRA-guided platinum-based 
chemotherapy and empirical chemotherapy were not different in 
chemo-naïve, unsesectable NSCLC.
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